Table 2.
Overall survival and first-line progression-free survival by treatment arm and histologic subtype
| Subtype | Everolimus | Sunitinib | ||||
|---|---|---|---|---|---|---|
| n | Median OS, mo (95% CI) | Median PFS, mo (95% CI) | n | Median OS, mo (95% CI) | Median PFS, mo (95% CI) | |
| Papillary | 13 | 14.9 (7.1–22.7) | 4.1 (1.5–7.4) | 14 | 16.6 (5.9–NA) | 5.7 (1.4–19.8) |
| Chromophobe | 6 | 25.1 (4.7–NA) | NA | 6 | 31.6 (14.2–NA) | 8.9 (2.9–20.1) |
| Unclassified | 6 | NA | 4.7 (2.6–NA) | 4 | 15.4 (NA) | 9.4 (3.3–15.4) |
| Translocation | 4 | 8.1 (5.5–23) | 3.0 (1.3–NA) | 3 | 16.2 (8.8–NA) | 6.1 (6.0–8.8) |
| Clear cell with >20% sarcomatoid features | 6 | 11.1 (2.0–NA) | 1.9 (1.0–23.4) | 6 | 7.0 (5.4–10.4) | 3.5 (1.3–7.7) |
CI = confidence interval; NA = not applicable; OS = overall survival; PFS = progression-free survival.